RiverVest Venture Partners focuses exclusively on life sciences, in particular in the medical device and biopharmaceutical industries. RiverVest also invests in select later-stage life science companies to diversify risk and maximize portfolio return...Show all
Phone: 314-726-6700
101 South Hanley Road
Suite 1850
St. Louis, 63105
Missouri, United States
Date | Company | Round | Amount | Co-investors |
---|---|---|---|---|
2020-12-09 | Reneo Pharmaceuticals | Series B | $95M | Abingworth, Accelerator Life Science Partners, Aisling Capital, Amzak Health, Lundbeckfond Ventures, New Enterprise Associates, Novo Ventures, Pappas Ventures, Rock Springs Capital, and Undisclosed Investors |
2020-05-21 | Good Therapeutics | Series A - II | $11M | 3x5 Partners, Codon Capital, Digitalis Ventures, and Roche Venture Fund |
2020-04-27 | Avalyn Pharma | Series B | $35.5M | Deerfield Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Pivotal bioVenture Partners, and TPG Biotech |
2020-03-02 | Xilio Therapeutics | Series B | $100.5M | Atlas Venture, Bay City Capital, F-Prime Capital, Ipsen Group, M Ventures, MRL Ventures, Solasta Ventures, SV Health Investors, and Takeda Ventures |
2020-02-20 | Spruce Biosciences | Series B | $88M | Abingworth, Aisling Capital, HealthCap Partners, Novo Ventures, Omega Fund Management, Rock Springs Capital, Sands Capital, and Surveyor Capital |